Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Key Highlights
- ➤ALTITUDE-AD topline results expected in November 2026
- ➤Cash, equivalents and marketable securities totaled $78.6 million
- ➤Cash expected to support clinical and operational activities into early 2027
- ➤Q3 net loss $25.4 million versus $26.5 million year over year
- ➤EBD lead-candidate IND filing targeted for mid-2027
Expert Statements
Daniel O’Connell, Chief Executive Officer of Acumen Pharmaceuticals
“In the third quarter, we continued readying for the readout from our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, and today I’m pleased to announce that we expect to report topline results in November 2026.”
Daniel O’Connell, Chief Executive Officer of Acumen Pharmaceuticals
“We remain encouraged by the potential for sabirnetug to become a treatment of choice, with a differentiated benefit-risk profile driven by its unique attributes as an anti-AβO IgG2 monoclonal antibody.”
Daniel O’Connell, Chief Executive Officer of Acumen Pharmaceuticals
“Another important piece of Acumen’s value proposition is our Enhanced Brain Delivery™ program, combining a validated blood-brain barrier-penetrating technology with an AβO-selective therapeutic antibody.”
Daniel O’Connell, Chief Executive Officer of Acumen Pharmaceuticals
“We continue to make progress on IND-enabling activities in support of a mid-2027 IND submission for a lead candidate and remain encouraged about the potential it holds as a next-generation Alzheimer’s disease treatment.”
* Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026 * IND filing for the Enhanced Brain Delivery™ (EBD(®)) program lead clinical candidate targeted for mid-2027 * Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027 * Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2026 and provided a business update.
Get started
Create a free account to read the full story.